Co-Development Agreement with Pfizer and Merck KGaA

Co-Development Agreement with Pfizer and Merck KGaA

Phase 2 BRACELET-1 study will evaluate Oncolytics' oncolytic virus pelareorep in combination with anti-PD-L1 BAVENCIO®

Despite the surge of novel immuno-oncology drugs, many patients still face resistance. Metastatic breast cancer, for example, is associated with high relapse rates and poor prognoses with limited treatment options. However, studies have shown that oncolytic viruses have the power to enhance existing cancer treatments by turning cold tumors that are no susceptible to immunotherapies, into hot tumors that are susceptible to treatment, including checkpoint blockade.

In June we announced our co-development agreement with Pfizer and Merck KGaA to investigate the combination of our immuno-oncology virus pelareorep with BAVENCIO® to treat patients with hormone-receptor positive, human epidermal growth factor 2-negative (HR+ / HER2-) metastatic breast cancer in the study BRACELET-1. As our oncolytic virus can create an inflamed phenotype to prime the immune system for checkpoint blockade by Merck KGaA’s anti-PD-L1 antibody, we have the opportunity to improve treatment outcomes.

Matt Coffey said in a conference call held after the announcement: “For Oncolytics, the BRACELET-1 study is strategically important for a number of reasons. Firstly, it allows us to collaborate with two of the world's leading pharma companies, but it also provides Oncolytics with the opportunity to confirm the highly encouraging overall survival data from our phase 2 IND 213 study conducted in the same patient population. It enables us to explore potential synergies between BAVENCIO and pelareorep on top of standard care, which is paclitaxel. And third, it further validates our predictive and prognostic biomarkers through another randomized study with a leading checkpoint inhibitor.”

For more information on the collaboration, see the full release here and listen to the full webcast from which the above excerpts were taken.